Printer Friendly

Ocular Therapeutix Touts Positive Topline Data in Post-Surgical Ocular Inflammation, Pain Trial.

M2 PHARMA-March 10, 2015-Ocular Therapeutix Touts Positive Topline Data in Post-Surgical Ocular Inflammation, Pain Trial

(C)2015 M2 COMMUNICATIONS

US-based biopharmaceutical company Ocular Therapeutix, Inc. (NASDAQ: OCUL) has received positive topline data from the first of two Phase 3 clinical trials evaluating the safety and efficacy of its lead product candidate, OTX-DP (Sustained Release Dexamethasone), for the treatment of ocular inflammation and pain following cataract surgery, the company said on Tuesday.

The Phase 3a study, which enrolled 247 patients, met both primary efficacy measures, achieving a statistically significant improvement in the reduction of inflammatory cells and pain.

According to the company, 33.7% of OTX-DP-treated patients showed an absence of inflammatory cells in the anterior chamber of the study eye on day 14 following drug product insertion, compared to 14.6% of those receiving placebo vehicle control punctum plug (p=0.0015).

In addition, 76.1% of patients receiving OTX-DP reported absence of pain in the study eye on day eight following insertion of the drug product, compared to 36.1% of those receiving placebo vehicle control punctum plug.

Ocular is continuing to analyze the safety findings from the clinical trial.

OTX-DP is a product candidate placed in the canaliculus and designed to deliver dexamethasone to the ocular surface for approximately four weeks.

Following treatment, OTX-DP resorbs and exits the nasolacrimal system without need for removal. In November 2014, the company announced encouraging data from its Phase 2 clinical trial evaluating the safety and efficacy of OTX-DP in allergic conjunctivitis and the company plans to initiate Phase 3 clinical trials for this indication in the middle of 2015.

The company also initiated an exploratory Phase 2 clinical trial of OTX-DP for the treatment of inflammatory dry eye in January 2015. The company is currently enrolling patients into a Phase 2b clinical trial of its second sustained release product candidate, OTX-TP (Sustained Release Travoprost), for the treatment of glaucoma and ocular hypertension.

Data from this trial is expected in 4Q15.

Two prospective, multicenter, randomized, parallel-arm, double-masked, vehicle-controlled Phase 3 clinical trials, referred to as the Phase 3a and Phase 3b clinical trials, were completed with a total of 487 patients (247 patients in Phase 3a and 240 in Phase 3b) undergoing unilateral clear corneal cataract surgery.

Patients were randomized 2: 1 to receive either OTX-DP or a placebo vehicle control punctum plug without active drug.

Both primary efficacy measures, differences in the proportion of patients in each treatment group with absence of cells in the anterior chamber of the study eye, as measured using slit lamp examination, at day 14 and absence of pain, as graded by a patient-reported score of zero on a scale from zero to ten, at day eight were recorded at each study visit.

Secondary efficacy measures were absence of flare in the anterior chamber of the study eye at each evaluation date and absence of inflammatory cells in the anterior chamber of the study eye and absence of pain in the study eye at each evaluation date other than the day used for the primary efficacy measure.

Topline data from the Phase 3b clinical trial are expected to be announced by the end of March. If the company obtains favorable aggregate results for both the Phase 3a and Phase 3b clinical trials, the company expects to submit a New Drug Application for OTX-DP for post-surgical ocular inflammation and pain in the second quarter of 2015.

The company said it believes that OTX-DP is the first sustained release drug-eluting corticosteroid punctum plug to enter and complete Phase 3 clinical trials.

Ocular inflammation and pain are common side effects following ophthalmic surgery. Physicians prescribe anti-inflammatory drugs, such as corticosteroids, as the standard of care. If left untreated, inflammation of the eye may result in further ocular complications, including scarring and vision loss.

((Comments on this story may be sent to info@m2.com))
COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 10, 2015
Words:645
Previous Article:Advanced Bionics Receives CE Mark for Cochlear Implant Use in Single-Sided Deafness Patients.
Next Article:Glide Technologies extends subcontract with Pfenex.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters